Patients with unresectable stage III non–small cell lung cancer who received durvalumab had their overall and progression-free survival boosted by about 12 months, compared with patients who received a placebo, according to results of the multicenter, randomized, double-blind, placebo-controlled, phase 3 PACIFIC trial published in the New England Journal of Medicine (2018 Sep 25. doi: 10.1056/NEJMoa1809697).
We covered this story at the World Conference on Lung Cancer before it was published in the journal. Find our coverage at the link below.